Thursday, 4 March 2021

Nuclear Medicine Market is Growing Massively till 2023

 Market Research Future (MRFR)’s report highlights that the global nuclear medicine market is likely to strike a CAGR of 6.2% during the forecast period 2018 to 2023. The valuation of the market is expected to witness a growth of USD 5.430 Bn by the end of 2023. The growth of the market is dictated by increasing incidences of target conditions such as Cardiovascular Diseases (CVD) and cancer. Furthermore, the exponentially growing geriatric population is poised to add to the patient pool. The rising inclination towards the use of radiopharmaceuticals for the treatment of geriatric population is prognosticated to generate significant demand for nuclear medicines in the foreseeable future.

The market looks lucrative and is expanding at a significant pace. It is anticipated to witness constant growth over the next couple of years owing to increasing applications, discoveries, etc. Nevertheless, the expensiveness of the radiopharmaceuticals and side effects related to radiation exposure remain impediments to the market proliferation.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6674

Report Coverage:

The report covers an in-depth study of the historical trends, current market status, forecast, and key players’ market share analysis. It also encompasses market factor analysis which includes supply chain analysis and Porter’s five forces analysis. The market is analyzed in detail by region as well as segmentation, and, a country-level analysis for each segment is also available in the report.

Report Overview:

This MRFR’s report offers a detailed five-year forecast (2018 to 2023) for the global nuclear medicine market. It reflects a revenue analysis of the different product types, including diagnostic nuclear medicine and therapeutic radiopharmaceuticals. The major applications discussed in the study encompasses diagnostic applications and therapeutic applications. The report also presents a detailed analysis of the end-users such as hospitals & diagnostic centers, research institutes, and others. A regional assessment of the market is published in the report for enhanced lucidity, which covers Americas, Europe, Asia Pacific, and the Middle East & Africa.

Companies Covered:

Some of the key players operating in the market are Cardinal Health, GE Healthcare, Bayer, Bracco Imaging, Curium, Lantheus Medical Imaging, Nordion Inc., Advanced Accelerators Applications, Mallinckrodt Pharmaceuticals, Jubliant Lifesciences, and Medtronic plc.

Research Methodology:

MRFR strives to leverage its industry expertise for offering insightful conclusions into the market that reflects the latest trends and foresight. Analytical algorithms are utilized for assessing and challenging the data curated through extensive primary and secondary research. The credible sources referred for data collection include interviews, SEC filings, whitepaper references, paid database services, etc. A multi-layer verification process authenticates the premium quality and reliability of the statistical observations offered in the report. Additionally, top-down and bottom-up approaches are employed for re-validating the accuracy of the quantitative assessment of the market.

Market Segmentation

MRFR has conducted a detailed study of the various parts of the nuclear medicine market which has been segmented on the basis of product type, application, end-user, and region. By product types, the nuclear medicine market has been segmented into diagnostic nuclear medicine and therapeutic radiopharmaceuticals. At present, the diagnostic nuclear medicine segment has attained a leadership position. However, the therapeutic radiopharmaceuticals segment is the fastest growing segment during the forecast period. The diagnostic nuclear medicine segment is segmented further into SPECT radiopharmaceuticals, and PET radiopharmaceuticals. Meanwhile, the therapeutic radiopharmaceuticals segment is sub-segmented into alpha emitters, beta emitters, and brachytherapy isotopes.

Applications of nuclear medicine are segmented into diagnostic applications and therapeutic applications. Diagnostic applications is a major segment which is sub-segmented into SPECT applications and PET applications. Meanwhile, the therapeutic applications segment is growing at the fastest pace.

End-users have been segmented into hospitals & diagnostic centers, research institutes, and others. Research institutes display the highest potential for growth over the forecast period, while hospitals & diagnostics centers have been identified as the most significant segment in terms of market share.

All sub-segments have been segmented further and included in the report.

Regional Analysis

The Americas due to the presence of North America has established itself as a market leader. The presence of several important market players combined with the high prevalence of cancer and other chronic diseases has influenced the growth of the Americas nuclear market. The region, particularly countries such as U.S & Canada have well-developed healthcare sectors which receive high investments. Moreover, the region has a high geriatric patient population which is expanding rapidly and is growing increasingly aware regarding advanced therapies.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/nuclear-medicine-market-6674

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com


Wednesday, 3 March 2021

Oral Thin Film Drugs Worldwide Market Research Report 2027

 Oral thin films (OTF) are an innovative method discovered by pharmaceutical scientists for delivering drugs orally or bucally (absorption or dissolution in the mouth). OTF drugs have gained popularity owing to its rapid dissolution on contact with saliva. The global oral thin film drugs market is predicted to exhibit an 8.10% CAGR from 2019 to 2027 (forecast period), as per the latest report by Market Research Future (MRFR). This can be credited to the expanding geriatric population and their need for advanced drug delivery methods to keep chronic diseases such as diabetes at bay. Continuous investment in research and development (R&D) by companies to create easily dissolvable solutions for other diseases is expected to spur market growth over the forecast period. Introduction of OTF drugs in developing countries can act as a good revenue source for the OTF drugs market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6547

Report Overview

The report provides an accurate overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global oral thin film drugs market segmented on the basis of product, disease indication, distribution channel, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.

Segment Overview

The global oral thin film drugs market is segmented by product, disease indication, and distribution channel. By product, the market is divided into sublingual and fast dissolving buccal film.  By disease indication, the market is segmented into opioid dependence, migraine, schizophrenia, and nausea and vomiting, and others. Distribution channel discussed in the report include hospital pharmacies, retail pharmacies, online drug stores, and others. The segments covered in the oral thin film drugs market report are analyzed with respect to four main regions namely – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA), with respective country-level market sizing. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market ladder.

Competitive Landscape

Prominent players in the oral thin film drugs market include Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), CURE Pharmaceutical (U.S.), Novartis AG (Switzerland), LTS Lohmann Therapie-Systeme AG (Germany), GlaxoSmithKline Plc (U.K.), and Indivior Plc (U.S.).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/oral-thin-film-drugs-market-6547

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com


Rhabdomyosarcoma Market to Witness an Outstanding Growth by 2023

 The global rhabdomyosarcoma market is expected to grow significantly over the forecast period. It is estimated that the global rhabdomyosarcoma market is expected to register a CAGR ~ 4.8 % during the forecast period of 2018–2023. Rhabdomyosarcoma is a type of cancerous tumor that starts to develop in the soft tissues of the body. Cells affected by rhabdomyosarcoma can grow and spread very fast.

Numerous factors such as raising awareness of rhabdomyosarcoma and its increasing prevalence are expected to drive the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6569

Moreover, favorable healthcare investments by government and the rising demand for better treatments boosts the growth of the market. However, stringent government regulation for product approval and huge costs of the treatment may hamper the market growth during the assessment period.

Segmentation

The global rhabdomyosarcoma market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma.

The market, by diagnosis, has been segmented into Imaging Tests and Biopsy.

Imaging tests are further segmented into X-Ray, MRI scan, CT scan, PET scan, and Bone Scan.

Biopsy is further segmented into Needle Biopsy and Surgery Biopsy.

The market, by treatment, has been segmented into Surgery, Radiation Therapy, Chemotherapy and Stem Cell Therapy. Chemotherapy is expected to account for the largest market share due to its effective treatment for minimizing the risk of cancer reoccurrence and high preference among the patients. Radiation therapy is anticipated to be the fastest growing segment due to technological advancements in the segment.

The market, by region, has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rhabdomyosarcoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European rhabdomyosarcoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The rhabdomyosarcoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rhabdomyosarcoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma are some of the key players in the global rhabdomyosarcoma market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/rhabdomyosarcoma-market-6569

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com


Benzathine Penicillin G Market - Factors Driving Growth Post 2023

 Benzathine Penicillin G is a formulation of two penicillin G molecules. Benzathine Penicillin G is a treatment used for various bacterial infections such as bejel, diphtheria, rheumatic fever, and also syphilis a sexually transmitted infection caused by the Treponema pallidum bacteria. Benzathine Penicillin G is also used to treat respiratory infections caused due to bacteria and viruses. It functions by inhibiting the growth of bacterial and viral infections in the human body. The key factors responsible for causing bacterial and viral infections are decrease in immunity due to change in lifestyle and having unhygienic food and other which supports the growth of the Benzathine Penicillin G market. According to the Centers for Disease Control and Prevention, December 2015, 21.2 million women of the age group of 14 to 49 years were affected by the bacterial vaginosis infection in the US. Such a high prevalence of bacterial infection can influence the market positively.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6541

However, factors such as allergies and side effects associated with treatments are expected to restrict the market growth during the forecast period.

Segmentation

The global Benzathine Penicillin G market is segmented on the basis of application, mode of injection, and end user. The Benzathine Penicillin G market, by the application, is segmented into bacterial infections and sexually transmitted infection (STI) syphilis treatment. Bacterial infections are further segmented into Bejel, diphtheria, and rheumatic fever.

On the basis of mode of injection, the market is segmented into intravenous and intramuscular injection. On the basis of the end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

On the basis of region, the global Benzathine Penicillin G market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players

Some of the key players in the global Benzathine Penicillin G market are Pfizer Inc, Alembic IT Department, ECPlaza Network Inc, Abcam plc, Sandoz International GmbH, Merck KGaA, Triveni Interchem Private Limited, CSC Pharmaceuticals, and others.

Regional Market Summary

It is estimated that North America dominated the global Benzathine Penicillin G market owing to the increasing bacterial infection, innovations in clinical practice, bacterial research, and access to viral and bacterial infection treatments in this region. According to the Centers for Disease Control and Prevention 27,814 cases of syphilis, a sexually transmitted infection was reported in the US in 2016. Such a high number of bacterial infection cases in this region influences the market growth in this region.

Europe stood the second largest in the Benzathine Penicillin G market owing to the increasing cases of rheumatic fever. According to the European Centre for Disease Prevention and Control (ECDC), June 2017, 850 000 cases of infectious diseases were notified in Europe in 2014. This number of cases is expected to increase during the forecast period. Such a high incidence rate of infectious diseases supports the growth of the Benzathine Penicillin G market in this region.

Asia-Pacific was estimated to be the fastest growing region for the global Benzathine Penicillin G market in 2017. The market is expected to witness growth owing to the rising prevalence of bacterial infection, increasing cases of respiratory infections, and changing lifestyle.

The Middle East and Africa holds the least share in the global Benzathine Penicillin G market due to the presence of low health expenditure and low awareness of therapeutic treatments. However, the market is expected to witness growth due to increasing healthcare programs and an increase in investments in research and development in this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/benzathine-penicillin-g-market-6541

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com


Spirometry Market to Witness an Outstanding Growth by 2023

 The global spirometry market is predicted to exhibit a 10.03% CAGR from 2018 to 2023 (forecast period) to reach USD 1,106.76 million by 2023, as per the latest report by Market Research Future (MRFR). This can be attributed to the sharp rise in the cases of chronic obstructive pulmonary disorders (COPD) and asthma.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6539

Spirometry is a basic test conducted by clinicians to evaluate the status of lungs. It is vital for diagnosing asthma, COPD, and other breathing disorders. The tests are carried out with the help of spirometers. Factors such as the increasing elderly populace, constrained budgets of healthcare institutes, and technological advances of respiratory care devices can drive the market demand over the forecast period. Initiatives taken by governments to curb smoking, home utilization spirometers, and focus on monitoring respiratory diseases can further the spirometry market till 2023.

Report Overview

The report provides an accurate overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global spirometry market segmented on the basis of product, technology, application, end-user, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.

Spirometry Market Segment Overview

The global market is segmented by product, technology, application, and end-user. Various products in the market include table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. Based on technology, the market is segmented into volume measurement spirometry, peak flow meters (PFM), and flow measurement spirometry.

By application, the spirometry market is segmented into diagnostic and treatment monitoring. The former is further segmented into COPD, asthma, and interstitial pulmonary fibrosis. End-users in the market include research & academic institutes, diagnostic centers, hospitals & clinics, and home care.

The segments covered in the spirometry market report are analyzed with respect to four main regions – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA), with respective country-level market sizing. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market ladder.

Spirometry Market – Competitive Landscape

Prominent players in the spirometry market include Carefusion Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Nihon Kohden Corporation (Germany), MGC Diagnostics Corporation (U.S.), Vitalograph (U.K.), Schiller AG (Switzerland), COSMED srl (Italy), Hill-Rom Holdings, Inc. (U.S.), Midmark Corporation (U.S.), Smiths Medical Inc. (U.S.), and Koninklijke Philips N.V. (The Netherlands).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com


Global Respiratory Care Devices Market Racing to a Heightened Growth by 2023

 The global respiratory care devices market is expected to register a significant growth at 10.1% CAGR during the forecast period (2018–2023).

The respiratory care devices are used for treatment, assessment, diagnosis, and care of patients suffering from cardiopulmonary devices. Respiratory care devices are used in the treatment of lung diseases such as chronic bronchitis, tuberculosis, acute and chronic pulmonary diseases, asthma, and others. With the growing age, the function of lungs starts to decline and hence the respiratory system undergoes various physiological, functional and immunological changes. The market growth is due to the rising incidences of chronic pulmonary diseases, asthma, and others. These devices can be used in hospitals and in-home care settings as they have developed from stationary to portable ones.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6517

Factors such as the increasing frequency of respiratory diseases, increasing geriatric population, urbanization, and its adverse effects, and changes in the environment and lifestyle boosts the growth of the market. The growing demand for point-of-care diagnostic devices in developing regions is anticipated to provide new opportunities for players in the respiratory care devices market. The lack of awareness about respiratory problems, intense competition, and the cost associated with the device and the respiratory surgery hamper the growth of the market.

Segmentation

The global respiratory care devices market has been segmented on the basis of therapeutic devices, monitoring devices, diagnostic devices, accessories and consumables, application, and end-users.

On the basis of therapeutic devices, the market has been classified as pap devices, masks, ventilators, nebulizers, humidifiers, oxygen concentrators, inhalers, reusable resuscitators, nitric oxide delivery units, and oxygen hoods.

On the basis of monitoring devices, the market has been classified as pulse oximeters, pulse oximeter sensors, pulse oximeter equipment, capnographs, and gas analyzers.

On the basis of diagnostic devices, the market has been classified as spirometers, polysomnography (PSG) devices, peak flow meters, and other diagnostic devices.

On the basis of accessories and consumables, the market has been classified as disposable masks, disposable resuscitators, tracheostomy tubes, nasal cannulas, and other consumables and accessories.

On the basis of application, the market has been classified as chronic obstructive pulmonary disease (COPD), sleep apnea, asthma, infectious diseases, and other diseases.

On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory care, home care, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European respiratory care devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The respiratory care devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The respiratory care devices market in the Middle East and Africa has been segmented into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com


Wearable Injectors Market – A market with high CAGR and return on investment by 2023

 The global wearable injectors market is expected to grow significantly over the forecast period. It is estimated that the global wearable injectors market is expected to register a CAGR of ~ 15.2% during the forecast period from 2018 to 2023. Wearable Injectors are medical devices designed to dispense large doses of the drug. Wearable Injectors are user-friendly, convenient and they lessen the need for multiple painful injections.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6491

Numerous factors such as growing demand of convenient methods of drug administration, rising prevalence of chronic diseases such as diabetes, technological advancements and design development in wearable injectors are expected to drive the growth of the market. For instance, in July 2016, Amgen received US Food and Drug Administration (FDA) approval for its on-body wearable injector, Repatha (evolocumab) Pushtronex system, a human monoclonal antibody injector.

Moreover, favorable healthcare investments by government and the rising demand for minimally invasive devices boosts the growth of the market. However, stringent government regulation for product approval and the growing preference for traditional methods of drug delivery may hamper the market growth during the assessment period.

Segmentation

The global wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.

The market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.

The market, by usage, has been segmented into disposable and semi-reusable.

The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.

The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.

The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the global wearable injectors market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.

Europe is expected to hold the second largest position in the global wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/wearable-injectors-market-6491

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com